title: Reply.
authors.affiliation: London, United Kingdom.
authors.forename: Namritha V
authors.initials: NV
authors.lastname: Patrao
authors.affiliation: London, United Kingdom.
authors.forename: Sheelah
authors.initials: S
authors.lastname: Antao
authors.affiliation: London, United Kingdom.
authors.forename: Catherine
authors.initials: C
authors.lastname: Egan
authors.affiliation: London, United Kingdom.
authors.forename: Amer
authors.initials: A
authors.lastname: Omar
authors.affiliation: London, United Kingdom.
authors.forename: Robin
authors.initials: R
authors.lastname: Hamilton
authors.affiliation: London, United Kingdom.
authors.forename: Philip G
authors.initials: PG
authors.lastname: Hykin
authors.affiliation: London, United Kingdom.
authors.forename: Sobha
authors.initials: S
authors.lastname: Sivaprasad
authors.affiliation: London, United Kingdom.
authors.forename: Ranjan
authors.initials: R
authors.lastname: Rajendram
authors.affiliation: London, United Kingdom.
mesh_terms: D003930:Diabetic Retinopathy; D006801:Humans; D008269:Macular Edema; D009313:National Health Programs; D000069579:Ranibizumab; D006113:United Kingdom
chemical_list: D000069579:Ranibizumab